




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## COVID-19 Rapid Letter

## Is low dose radiation therapy a potential treatment for COVID-19 pneumonia? ☆

Charles Kirkby<sup>a,b,c</sup>, Marc Mackenzie<sup>d</sup><sup>a</sup> Department of Medical Physics, Jack Ady Cancer Centre, Lethbridge; <sup>b</sup> Department of Oncology; <sup>c</sup> Department of Physics and Astronomy, University of Calgary; and <sup>d</sup> Department of Oncology, University of Alberta, Edmonton, Canada

Fatal cases of COVID-19 are characterised by acute respiratory distress syndrome (ARDS), sepsis, pneumonia and respiratory failure [1]. The high transmission rate of the virus and the corresponding rapid escalation in the number of infections has resulted in unprecedented strains on healthcare systems worldwide, particularly as healthcare workers struggle to treat COVID-19 pneumonia.

We would like to draw the radiotherapy community's attention to the potential for low doses (<100 cGy) of low LET radiation to treat viral pneumonia as a possible therapy for COVID-19 patients. It was not uncommon in the early twentieth century to treat pneumonia with X-rays. A review showed low doses from kilovoltage X-rays reduced pneumonia mortality from roughly 30 percent to 10 percent on average [2]. Doses reported were generally in the 20 – few hundred Roentgen range, which given the attenuation through chest wall would likely have resulted in mean lung doses in the tens to <100 cGy range. Some reports noted rapid symptom relief on the order of hours [3,4]. Animal models suggested LDRT could reduce the acute phase of pneumonia by half [5]. In light of the current mortality rates associated with COVID-19 pneumonia, it is therefore reasonable to re-examine this old treatment.

Pneumonia arises as an inflammatory immune response to infection when the alveoli become inflamed and secrete fluid compromising their gas exchange function. In a viral infection, viruses trigger immune cells to synthesize pro-inflammatory cytokines and chemokines [6], inciting the immune response. Historical evidence points to the induction of an anti-inflammatory phenotype induced by low doses of radiation as a potential explanation for the observed effects [2]. While doses  $\geq 200$  cGy tends to exert pro-inflammatory effects, triggering common toxicities observed in radiation therapy, more recent work shows low doses (<100 cGy) incite anti-inflammatory properties [7,8] such as decreasing levels of pro-inflammatory cytokines like IL-1 $\beta$  [9], or

inhibiting leukocyte recruitment [10]. Therefore, it stands to reason that an LDRT treatment of 30–100 cGy to the lungs of a patient with COVID-19 pneumonia could reduce the inflammation and relieve the life-threatening symptoms.

A single fraction 30–100 cGy treatment could easily be delivered on a conventional megavoltage radiation therapy unit. Routinely, much higher, single fraction doses are delivered in a palliative context with fast-tracked patients going through the full workflow process of education, scanning, planning and treatment delivery in a matter of hours. Proof of principle simulations suggest that a POP treatment with a megavoltage beam could easily ensure 99% of the whole lung volume received between 90% and 120% of a 70 cGy prescribed dose. And because of the low doses, common radiotherapy toxicities would be avoided.

While a large scale up of such LDRT treatments would not be without obstacles (e.g. existing strain on radiotherapy resources, separating COVID-19 patients and cancer patients, etc.), we believe clinical trials to further investigate the efficacy of whole lung LDRT would present a very low risk to COVID-19 pneumonia patients, and have the potential to reduce mortality and alleviate COVID-19 related strains on healthcare systems.

## References

- [1] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with covid-19 in Wuhan, china: a retrospective cohort study. *Lancet* 2020.
- [2] Calabrese EJ, Dhawan G. How radiotherapy was historically used to treat pneumonia: could it be useful today?. *Yale J Biol Med* 2013;86:555–70.
- [3] Powell EV. Radiation therapy of lobular pneumonia. *Texas State J Med* 1936;32:237–40.
- [4] Oppenheimer A. Roentgen therapy of interstitial pneumonia. *J Pediatr* 1943;41:404–14.
- [5] Dubin IN, Baylin CJ, Gobble Jr WG. The effect of roentgen therapy on experimental virus pneumonia; on pneumonia produced in white mice by swine influenza virus. *Am J Roentgenol Radium Ther* 1946;55:478–81.
- [6] Moldoveanu B, Otmishi P, Jani P, et al. Inflammatory mechanisms in the lung. *J Inflamm Res* 2009;2:1–11.
- [7] Rodel F, Keilholz L, Herrmann M, et al. Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy. *Int J Radiat Biol* 2007;83:357–66.
- [8] Torres L, Royo, Antelo G, Redondo, Arquez M, Pianetta, et al. Low-dose radiation therapy for benign pathologies. *Rep Pract Oncol Radiother* 2020;25:250–4.
- [9] Schae D, Jahns J, Hildebrandt G, et al. Radiation treatment of acute inflammation in mice. *Int J Radiat Biol* 2005;81:657–67.
- [10] Arenas M, Gil F, Gironella M, et al. Time course of anti-inflammatory effect of low-dose radiotherapy: Correlation with tgf-beta(1) expression. *Radiother Oncol* 2008;86:399–406.

☆ The Editors of the Journal, the Publisher and the European Society for Radiotherapy and Oncology (ESTRO) cannot take responsibility for the statements or opinions expressed by the authors of these articles. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. For more information see the editorial "Radiotherapy & Oncology during the COVID-19 pandemic", Vol. 146, 2020.

E-mail address: charles.kirkby@ahs.ca (C. Kirkby)